Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 178
- Registration Number
- NCT00612040
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Umeå, Sweden
Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 477
- Registration Number
- NCT00604396
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Umeå, Sweden
Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 401
- Registration Number
- NCT00604344
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 193
- Registration Number
- NCT00605111
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand
Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone
Phase 3
Completed
- Conditions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 362
- Registration Number
- NCT00604253
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 719
- Registration Number
- NCT00605020
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 241
- Registration Number
- NCT00604656
- Locations
- 🇵🇱
Novo Nordisk Investigational Site, Wroclaw, Poland
Safety of Insulin Detemir in Children With Type 1 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 83
- Registration Number
- NCT00605137
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1
- Registration Number
- NCT00601861
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 71
- Registration Number
- NCT00600366
- Locations
Novo Nordisk Investigational Site, Novi Sad, Former Serbia and Montenegro
© Copyright 2024. All Rights Reserved by MedPath